US 11,497,781
Application 16/083,709 · Granted Nov 15, 2022
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus cg0070 and an immune checkpoint inhibitor
Estimated expiration
March 9, 2037
10y 111d remaining
Earliest effective filing
Mar 9, 2017
+ 20 years
Mar 9, 2037
PTA +0d
Mar 9, 2037
No TD
—
Final
Mar 9, 2037
- Earliest effective filing
- Mar 9, 2017
- + 20 years
- Mar 9, 2037
- PTA +0d
- Mar 9, 2037
- No TD
- —
- Final
- Mar 9, 2037
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- September 10, 2018
- Earliest effective filing
- March 9, 2017
- Issue date
- November 15, 2022
- PTA
- 0 days
- Base expiry (before PTA)
- March 9, 2037
March 9, 2017 + 20 years = March 9, 2037
- National stage entry of application PCTUS2017021694, filed Mar 9, 2017
- PRO62/306,470 — Provisional — not used for base term
- PRO62/306,470 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 16/083,709 · US 11,497,781
PatentReply compiles the prosecution history behind US 11,497,781: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11497781Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.